Last reviewed · How we verify
NCT03732430: CARTAI
CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients
Phase 2 trial testing IBI308 in Thoracic Malignancies in 45 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Taizhou Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 14 November 2018 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- IBI308 — full drug profile →
Conditions studied
- Thoracic Malignancies — all drugs for Thoracic Malignancies →
Sponsor
Taizhou Hospital
Who can join
Adults 18 to 75, any sex, with Thoracic Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II study is to evaluate the safety and efficacy of CT-based adaptive radiation therapy followed by adjuvant anti-PD-1 antibody immunotherapy in treating patients with different types and stages of thoracic malignancies. (CARTAI)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03732430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IBI308
Trials testing the same drug.
- NCT04277663 — The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has · Phase 3 · terminated
- NCT04056949 — Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy · Phase 2 · unknown
- NCT03872661 — Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC · Phase 2 · recruiting
- NCT03568539 — IBI308 in Subjects With Advanced/Metastatic Solid Malignancies · Phase 1 · completed
- NCT03150875 — A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC · Phase 3 · completed
Other Taizhou Hospital trials
Trials by the same sponsor.
- NCT06997614 — Enhancing Critical Thinking Competency and Nursing Quality in Critically Ill Patient Care · NA · completed
- NCT06902935 — Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four · not yet recruiting
- NCT06441344 — Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell · Phase 3 · not yet recruiting
- NCT07127809 — Mindfulness-Based Intervention Targeting Psychological Capital to Reduce Job Burnout Among Nurses · NA · completed
- NCT06319950 — High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03732430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taizhou Hospital
- Last refreshed: 29 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing